Comparative Pharmacology
Head-to-head clinical analysis: ANGIOMAX versus HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOMAX versus HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5.
ANGIOMAX vs HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates, thereby inhibiting fibrin formation and activation of coagulation factors V, VIII, and XIII.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa), thereby preventing fibrin clot formation and extension.
1 mg/kg intravenous bolus followed by 0.1 mg/kg/hour continuous intravenous infusion for duration of procedure; alternatively, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg/hour continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention.
Loading dose: 5000 units IV bolus, then continuous IV infusion at 12,000-18,000 units/24h (10-15 units/kg/h). Adjust to target aPTT 60-80 seconds.
None Documented
None Documented
Terminal elimination half-life: 25-30 minutes in patients with normal renal function; increased to 2-3 hours in dialysis-dependent patients
The terminal elimination half-life of heparin is dose- and concentration-dependent, averaging 1-2 hours after intravenous administration. At therapeutic doses, the half-life is approximately 1.5 hours; with higher doses, it can extend to 2.5-3 hours. The half-life is prolonged in patients with hepatic or renal impairment.
Renal: ~90% unchanged; biliary/fecal: negligible (<1%)
Heparin is eliminated primarily via the reticuloendothelial system and liver, with renal excretion of metabolites accounting for approximately 50-60% of the dose. A small fraction (up to 5%) is excreted unchanged in urine. No significant biliary or fecal elimination.
Category C
Category A/B
Anticoagulant
Anticoagulant